effrey Becker

Bexson Biomedical, a private company in the psychedelics space, has inked a new agreement with Stevanato Group, an Italian-based provider of drug delivery solutions. Bexson is currently developing an improved version of ketamine called BB106, which allows for subcutaneous delivery of the drug. The...